Transcripts of circulating tumor cells detected by a breast cancer-specific platform correlate with clinical stage in bladder cancer patients

Todenhöfer, Tilman; Hennenlotter, Jörg; Dorner, Nathalie; Kühs, Ursula; Aufderklamm, Stefan; Rausch, Steffen; Bier, Simone; Mischinger, Johannes; Schellbach, Doreen; Hauch, Siegfried; Feniuk, Natalie; Bedke, Jens; Gakis, Georgios; Stenzl, Arnulf; Schwentner, Christian

doi:10.1007/s00432-016-2129-0

Cited by 18 publications

(20 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, the use of improved AdnaTest immune-magnetic systems also allowed the identification of CTC with stem-like features by PCR-based methods, showing that ALDH1 mainly contributed to CTC positivity compared to EPCAM , MUC1, or ERBB2 in bladder cancer patients [53]. …”

Section: Discussionmentioning

confidence: 99%

Detection of Circulating Tumour Cells in Urothelial Cancers and Clinical Correlations: Comparison of Two Methods

et al. 2017

View full text Add to dashboard Cite

Circulating tumour cells (CTC) are identified exploiting their protein/gene expression patterns or distinct size compared to blood cells. Data on CTC in bladder cancer (BC) are still scarce. We comparatively analyzed CTC enrichment by AdnaTest ProstateCancerSelect (AT) and ScreenCell®Cyto (SC) kits, combined with identification by EPCAM, MUC1, and ERBB2 expression and by cytological criteria, respectively, in 19 nonmetastatic (M0) and 47 metastatic (M+) BC patients, at baseline (T0) and during treatment (T1). At T0, CTC positivity rates by AT were higher in M+ compared to M0 cases (57.4% versus 25%, p = 0.041). EPCAM was detected in 75% of CTC-positive samples by AT, showing increasing expression levels from T0 to T1 (median (interquartile range, IQR): 0.18 (0.07–0.42) versus 0.84 (0.33–1.84), p = 0.005) in M+ cases. Overall, CTC positivity by SC was around 80% regardless of clinical setting and time point of analysis, except for a lower occurrence at T1 in M0 cases. At T0, circulating tumour microemboli were more frequently (25% versus 8%) detected and more numerous in M+ compared to M0 patients. The approach used for CTC detection impacts the outcome of CTC studies. Further investigations are required to clarify the clinical validity of AT and SC in specific BC clinical contexts.

show abstract

Section: Discussionmentioning

confidence: 99%

Detection of Circulating Tumour Cells in Urothelial Cancers and Clinical Correlations: Comparison of Two Methods

et al. 2017

View full text Add to dashboard Cite

show abstract

“…This classification is rather important as mesenchymal CTCs are frequently found in patients with metastatic stages of the disease, giving hints for prognosis and treatment [40,41,42]. EMT and stem cell specific transcripts were also shown to correlate with clinical stage and can be detected in patients negative for epithelial marker expression [43]. Thereof arises the necessity to identify different tumor cell subpopulations, which might be able by different methods, but also a standardization of these variegated techniques is important [44].…”

Section: Historical Backgroundmentioning

confidence: 99%

The Significance of Epithelial-to-Mesenchymal Transition for Circulating Tumor Cells

Kölbl

Jeschke

Andergassen

2016

IJMS

View full text Add to dashboard Cite

Epithelial to mesenchymal transition (EMT) is a process involved in embryonic development, but it also plays a role in remote metastasis formation in tumor diseases. During this process cells lose their epithelial features and adopt characteristics of mesenchymal cells. Thereby single tumor cells, which dissolve from the primary tumor, are enabled to invade the blood vessels and travel throughout the body as so called “circulating tumor cells” (CTCs). After leaving the blood stream the reverse process of EMT, the mesenchymal to epithelial transition (MET) helps the cells to seed in different tissues, thereby generating the bud of metastasis formation. As metastasis is the main reason for tumor-associated death, CTCs and the EMT process are in the focus of research in recent years. This review summarizes what was already found out about the molecular mechanisms driving EMT, the consequences of EMT for tumor cell detection, and suitable markers for the detection of CTCs which underwent EMT. The research work done in this field could open new roads towards combating cancer.

show abstract

“…In general, similarly to BC, mesenchymal CTCs seem to be associated with metastasis [43,134] and poor patient outcome [43,132] . Expression of EMT-related transcripts (PI3Kα, TWIST1 and AKT2) in CTCs from bladder cancer patients correlated with clinical stage and could be detected in patients negative for epithelial transcripts [137] .…”

Section: Clinical Significance Of Emt In Ctcsmentioning

confidence: 99%

“…Importantly, mesenchymal CTCs allowed a more accurate prediction of prognosis than the expression of epithelial markers alone [4] . Clinical significance of mesenchymal CTCs was examined not only in BC, but also in other cancers, including colorectal [43,132] , hepatocellular [133,134] , gastric [135] , prostate [41,136] , bladder [137] , ovarian [138] , endometrial [139] , and non-small cell lung cancer [140] . The majority of data concern the metastatic setting.…”

Section: Clinical Significance Of Emt In Ctcsmentioning

confidence: 99%

The Landscape of Circulating Tumor Cell Research in the Context of Epithelial-Mesenchymal Transition

Markiewicz

Żaczek²

2017

Pathobiology

View full text Add to dashboard Cite

The metastatic spread of cancer accounts for the vast majority of cancer-related deaths. It is mediated by tumor cells circulating in blood (called circulating tumor cells, CTCs), which escaped from their established niches. CTCs give a unique opportunity to look into the metastatic cascade and to study the molecular processes supporting the spread of tumor cells throughout the body. As current therapies are not sufficiently effective in treating metastatic disease, it is important to determine cellular and molecular features of cancer cells that “seed” new tumors in distant organs at early stages. In this review we focus on the role of the epithelial-mesenchymal transition program in providing a survival advantage to metastasizing tumor cells, especially CTCs, and put it in the context of clinical findings.

show abstract

Transcripts of circulating tumor cells detected by a breast cancer-specific platform correlate with clinical stage in bladder cancer patients

Cited by 18 publications

References 28 publications

Detection of Circulating Tumour Cells in Urothelial Cancers and Clinical Correlations: Comparison of Two Methods

Detection of Circulating Tumour Cells in Urothelial Cancers and Clinical Correlations: Comparison of Two Methods

The Significance of Epithelial-to-Mesenchymal Transition for Circulating Tumor Cells

The Landscape of Circulating Tumor Cell Research in the Context of Epithelial-Mesenchymal Transition

Contact Info

Product

Resources

About